WO2004082579A3 - Nemorubicin as radiosensitizer in combination with radiation therapy against tumors - Google Patents

Nemorubicin as radiosensitizer in combination with radiation therapy against tumors Download PDF

Info

Publication number
WO2004082579A3
WO2004082579A3 PCT/EP2004/050246 EP2004050246W WO2004082579A3 WO 2004082579 A3 WO2004082579 A3 WO 2004082579A3 EP 2004050246 W EP2004050246 W EP 2004050246W WO 2004082579 A3 WO2004082579 A3 WO 2004082579A3
Authority
WO
WIPO (PCT)
Prior art keywords
radiosensitizer
combination
radiation therapy
nemorubicin
against tumors
Prior art date
Application number
PCT/EP2004/050246
Other languages
French (fr)
Other versions
WO2004082579A2 (en
Inventor
Maria Cristina Rosa Geroni
Maria Adele Pacciarini
Antonino Suarato
Original Assignee
Pharmacia Italia Spa
Maria Cristina Rosa Geroni
Maria Adele Pacciarini
Antonino Suarato
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa, Maria Cristina Rosa Geroni, Maria Adele Pacciarini, Antonino Suarato filed Critical Pharmacia Italia Spa
Priority to BRPI0408494-2A priority Critical patent/BRPI0408494A/en
Priority to AU2004222526A priority patent/AU2004222526A1/en
Priority to EP04716607A priority patent/EP1603575A2/en
Priority to MXPA05009851A priority patent/MXPA05009851A/en
Priority to CA002519289A priority patent/CA2519289A1/en
Publication of WO2004082579A2 publication Critical patent/WO2004082579A2/en
Publication of WO2004082579A3 publication Critical patent/WO2004082579A3/en
Priority to NO20054349A priority patent/NO20054349L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a morpholinyl anthracycline derivative for use as radiosensitizer, to be administered in combination with radiation therapy, so that a synergistic effect can be revealed.
PCT/EP2004/050246 2003-03-18 2004-03-03 Nemorubicin as radiosensitizer in combination with radiation therapy against tumors WO2004082579A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BRPI0408494-2A BRPI0408494A (en) 2003-03-18 2004-03-03 combined tumor therapy comprising nemorubicin with radiation therapy
AU2004222526A AU2004222526A1 (en) 2003-03-18 2004-03-03 Nemorubicin as radiosensitizer in combination with radiation therapy against tumors
EP04716607A EP1603575A2 (en) 2003-03-18 2004-03-03 Nemorubicin as radiosensitizer in combination with radiation therapy against tumors
MXPA05009851A MXPA05009851A (en) 2003-03-18 2004-03-03 Nemorubicin as radiosensitizer in combination with radiation therapy against tumors.
CA002519289A CA2519289A1 (en) 2003-03-18 2004-03-03 Nemorubicin as radiosensitizer in combination with radiation therapy against tumors
NO20054349A NO20054349L (en) 2003-03-18 2005-09-20 Combined cancer therapy including nemorubicin with radiation therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03075781 2003-03-18
EP03075781.9 2003-03-18

Publications (2)

Publication Number Publication Date
WO2004082579A2 WO2004082579A2 (en) 2004-09-30
WO2004082579A3 true WO2004082579A3 (en) 2004-11-11

Family

ID=33016931

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/050246 WO2004082579A2 (en) 2003-03-18 2004-03-03 Nemorubicin as radiosensitizer in combination with radiation therapy against tumors

Country Status (8)

Country Link
EP (1) EP1603575A2 (en)
AU (1) AU2004222526A1 (en)
BR (1) BRPI0408494A (en)
CA (1) CA2519289A1 (en)
MX (1) MXPA05009851A (en)
NO (1) NO20054349L (en)
RU (1) RU2005132175A (en)
WO (1) WO2004082579A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007035489A2 (en) * 2005-09-16 2007-03-29 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating or preventing cancer using pyridine carboxaldehyde pyridine thiosemicarbazone radiosensitizing agents
EP2152236B1 (en) 2007-05-11 2015-09-02 Nerviano Medical Sciences S.r.l. Pharmaceutical composition of an anthracycline
WO2009099741A1 (en) 2008-02-01 2009-08-13 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
ES2532635T3 (en) 2008-07-15 2015-03-30 Genentech, Inc. Anthracycline conjugates, process for its preparation and its use as antitumor compounds
CN103270043B (en) 2010-12-02 2015-12-16 内尔维阿诺医学科学有限公司 For the preparation of the method for morpholinyl anthracycline derivatives
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
US20170312290A1 (en) * 2014-11-05 2017-11-02 Nerviano Medical Sciences S.R.L. Functionalized morpholinyl anthracycline derivatives

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4672057A (en) * 1985-03-22 1987-06-09 Farmitalia Carlo Erba S.P.A. Morpholino derivatives of daunorubicin and doxorubicin
US4710564A (en) * 1985-01-18 1987-12-01 Microbial Chemistry Research Foundation Anthracycline compounds
GB2296495A (en) * 1994-12-23 1996-07-03 Erba Carlo Spa Morpholine and piperidine N-oxide based anthracycline derivatives as antitumour agents
GB2315067A (en) * 1996-07-11 1998-01-21 Pharmacia Spa Morpholinyl bridged anthracycline derivatives
WO2003082267A1 (en) * 2002-04-02 2003-10-09 Pharmacia Italia Spa Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4710564A (en) * 1985-01-18 1987-12-01 Microbial Chemistry Research Foundation Anthracycline compounds
US4672057A (en) * 1985-03-22 1987-06-09 Farmitalia Carlo Erba S.P.A. Morpholino derivatives of daunorubicin and doxorubicin
GB2296495A (en) * 1994-12-23 1996-07-03 Erba Carlo Spa Morpholine and piperidine N-oxide based anthracycline derivatives as antitumour agents
GB2315067A (en) * 1996-07-11 1998-01-21 Pharmacia Spa Morpholinyl bridged anthracycline derivatives
WO2003082267A1 (en) * 2002-04-02 2003-10-09 Pharmacia Italia Spa Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"Preclinical activity against liver metastases of Nemorubicin, a DNA-intercalating cytotoxic agent for the treatment of hepatocellular carcinoma", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 38, November 2002 (2002-11-01), pages S19, XP004403483, ISSN: 0959-8049 *
"Properties of the new anthracycline derivative containing modified daunosamine moiety", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 38, November 2002 (2002-11-01), pages S19 - S20, XP004403485, ISSN: 0959-8049 *
"The combination of nemorubicin with cisplatin and mitomycin C is synergistic in experimental tumor models", November 2002, EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, PAGE(S) S20, ISSN: 0959-8049, XP004403486 *
BONNER J A ET AL: "Doxorubicin decreases the repair of radiation-induced DNA damage", 1990, INTERNATIONAL JOURNAL OF RADIATION BIOLOGY 1990 UNITED KINGDOM, VOL. 57, NR. 1, PAGE(S) 55-64, ISSN: 0020-7616, XP009033771 *
BONNER J A ET AL: "DOXORUBICIN ENHANCES RADIATION-INDUCED DNA DAMAGE", INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY, BIOLOGY, PHYSICS, vol. 15, no. SUPPL. 1, 1988, & 30TH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR THERAPEUTIC RADIOLOGY AND ONCOLOGY, NEW ORLEANS, LOU, pages 163, XP009033770, ISSN: 0360-3016 *
CHENOUFI NORCHEN ET AL: "In vitro demonstration of synergy between radionuclide and chemotherapy", JOURNAL OF NUCLEAR MEDICINE, vol. 39, no. 5, May 1998 (1998-05-01), pages 900 - 903, XP009033769, ISSN: 0161-5505 *
JAGETIA GANESH CHANDRA ET AL: "Effect of doxorubicin on cell survival and micronuclei formation in HeLa cells exposed to different doses of gamma-radiation", STRAHLENTHERAPIE UND ONKOLOGIE, vol. 176, no. 9, September 2000 (2000-09-01), pages 422 - 428, XP002289047, ISSN: 0179-7158 *
KABUTO M ET AL: "[Antitumor effect of MX2, a new morpholino anthracycline against C6 glioma cells and its combination effect with photodynamic therapy in vitro]", October 1995, NO TO SHINKEI. BRAIN AND NERVE. OCT 1995, VOL. 47, NR. 10, PAGE(S) 969 - 973, ISSN: 0006-8969, XP009033767 *
WU LI-TEH: "Doxorubicin as radiation potentiator: Concurrent doxorubicin and radiation therapy interaction and its clinical applications", INFUSION CHEMOTHERAPY: IRRADIATION INTERACTIONS: PRINCIPLES AND APPLICATIONS TO ORGAN SALVAGE AND PREVENTION OF SECOND PRIMARY NEOPLASMS ELSEVIER SCIENCE PUBLISHERS B.V., PO BOX 211, SARA BURGERHARTSTRAAT 25, 1000 AE AMSTERDAM, THE NETHERLANDS; ELSEV, 1998, pages 147 - 151, XP002289046, ISSN: 0-444-82608-4 *

Also Published As

Publication number Publication date
EP1603575A2 (en) 2005-12-14
BRPI0408494A (en) 2006-04-04
AU2004222526A1 (en) 2004-09-30
RU2005132175A (en) 2006-01-27
NO20054349L (en) 2005-10-11
CA2519289A1 (en) 2004-09-30
MXPA05009851A (en) 2005-12-06
WO2004082579A2 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
WO2004089415A3 (en) COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
WO2006065392A3 (en) Cancer treatments
WO2004058191A3 (en) Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
TWI350286B (en) Alkylpiperazine- and alkylhomopiperazine-carboxylate derivatives, their preparation and their application in therapy
WO2008085562A3 (en) Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies
WO2006042146A3 (en) Multifunctional nanoparticles conjugates and their use
MX279139B (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis.
PL1689724T3 (en) Quinazolinone compounds as anticancer agents
WO2009020802A3 (en) Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
IL174994A0 (en) Pyrimidin - 4 - yl - 3, 4 - thione compounds and their use in therapy
WO2004087158A3 (en) Muscarinic m1 receptor agonists for pain management
WO2005069994A3 (en) Folate conjugates and complexes
WO2005009460A3 (en) Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
WO2008002672A3 (en) Targets for use in diagnosis, prognosis and therapy of cancer
WO2007022408A3 (en) Combination methods of saha and targretin for treating cancer
WO2009071690A3 (en) 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases
WO2006046080A8 (en) Pegylated liposomal doxorubicin in combination with ecteinescidin 743
AP2006003537A0 (en) Use of polypeptides of the cupredoxin family in cancer therapy.
WO2007056236A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
AU2006251167A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
WO2006102375A3 (en) Methods for avoiding edema in the treatment or prevention of pparϝ-responsive diseases, including cancer
WO2008118733A3 (en) Methods of treating cancer by administering human il-18 combinations
WO2007133944A3 (en) Topical administration of acyclovir
DE502007001697D1 (en) MOBILE WINDOW AT THE COFFEE ENCLOSURE
ZA200711041B (en) Topical pain relief compositions of N,2,3-trimethyl-2-isopropylbutamide and methods for using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 200507102

Country of ref document: ZA

Ref document number: 542208

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 4025/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2519289

Country of ref document: CA

Ref document number: PA/a/2005/009851

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1-2005-501669

Country of ref document: PH

Ref document number: 170882

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2006505444

Country of ref document: JP

Ref document number: 20048071393

Country of ref document: CN

Ref document number: 1020057017377

Country of ref document: KR

Ref document number: 05094072

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2004716607

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004222526

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005132175

Country of ref document: RU

Ref document number: 1200501522

Country of ref document: VN

ENP Entry into the national phase

Ref document number: 2004222526

Country of ref document: AU

Date of ref document: 20040303

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004222526

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004716607

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020057017377

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0408494

Country of ref document: BR

WWW Wipo information: withdrawn in national office

Ref document number: 2004716607

Country of ref document: EP